Jessica M Ruck1, Dorry L Segev1,2. 1. Department of Surgery, Johns Hopkins University School of Medicine. 2. Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Due to the organ shortage, which prevents over 90 000 individuals in the United States from receiving life-saving transplants, the transplant community has begun to critically reevaluate whether organ sources that were previously considered too risky provide a survival benefit to waitlist candidates. RECENT FINDINGS: Organs that many providers were previously unwilling to use for transplantation, including kidneys with a high Kidney Donor Profile Index or from increased risk donors who have risk factors for window period hepatitis C virus (HCV) and HIV infection, have been shown to provide a survival benefit to transplant waitlist candidates compared with remaining on dialysis. The development of direct-acting antivirals to cure HCV infection has enabled prospective trials on the transplantation of organs from HCV-infected donors into HCV-negative recipients, with promising preliminary results. Changes in legislation through the HIV Organ Policy Equity Act have legalized transplantations from HIV-positive deceased donors to HIV-positive recipients for the first time in the United States. SUMMARY: Critical reexamination of deceased donor organs that were previously discarded has resulted in greater utilization of these organs, an increased number of deceased donor transplants, and the provision of life-saving treatment to more transplant waitlist candidates.
PURPOSE OF REVIEW: Due to the organ shortage, which prevents over 90 000 individuals in the United States from receiving life-saving transplants, the transplant community has begun to critically reevaluate whether organ sources that were previously considered too risky provide a survival benefit to waitlist candidates. RECENT FINDINGS: Organs that many providers were previously unwilling to use for transplantation, including kidneys with a high Kidney Donor Profile Index or from increased risk donors who have risk factors for window period hepatitis C virus (HCV) and HIV infection, have been shown to provide a survival benefit to transplant waitlist candidates compared with remaining on dialysis. The development of direct-acting antivirals to cure HCV infection has enabled prospective trials on the transplantation of organs from HCV-infecteddonors into HCV-negative recipients, with promising preliminary results. Changes in legislation through the HIV Organ Policy Equity Act have legalized transplantations from HIV-positive deceased donors to HIV-positive recipients for the first time in the United States. SUMMARY: Critical reexamination of deceased donor organs that were previously discarded has resulted in greater utilization of these organs, an increased number of deceased donor transplants, and the provision of life-saving treatment to more transplant waitlist candidates.
Authors: Allan B Massie; Abimereki D Muzaale; Xun Luo; Eric K H Chow; Jayme E Locke; Anh Q Nguyen; Macey L Henderson; Jon J Snyder; Dorry L Segev Journal: J Am Soc Nephrol Date: 2017-04-27 Impact factor: 10.121
Authors: J D Schold; L D Buccini; T R Srinivas; R T Srinivas; E D Poggio; S M Flechner; C Soria; D L Segev; J Fung; D A Goldfarb Journal: Am J Transplant Date: 2013-01 Impact factor: 8.086
Authors: E K H Chow; A B Massie; A D Muzaale; A L Singer; L M Kucirka; R A Montgomery; H P Lehmann; D L Segev Journal: Am J Transplant Date: 2013-05 Impact factor: 8.086
Authors: Sean M Wrenn; Peter W Callas; Trishul Kapoor; Alia F Aunchman; Adam N Paine; Jaime A Pineda; Carlos E Marroquin Journal: Pediatr Transplant Date: 2017-09-17
Authors: Jayme E Locke; Shikha Mehta; Rhiannon D Reed; Paul MacLennan; Allan Massie; Anoma Nellore; Christine Durand; Dorry L Segev Journal: J Am Soc Nephrol Date: 2015-03-19 Impact factor: 10.121
Authors: J M Garonzik-Wang; N T James; K C Weatherspoon; N A Deshpande; J A Berger; E C Hall; R A Montgomery; D L Segev Journal: Am J Transplant Date: 2011-10-12 Impact factor: 8.086
Authors: Mary G Bowring; Courtenay M Holscher; Sheng Zhou; Allan B Massie; Jacqueline Garonzik-Wang; Lauren M Kucirka; Sommer E Gentry; Dorry L Segev Journal: Am J Transplant Date: 2017-12-05 Impact factor: 8.086
Authors: Christine M Durand; Mary G Bowring; Diane M Brown; Michael A Chattergoon; Guido Massaccesi; Nichole Bair; Russell Wesson; Ashraf Reyad; Fizza F Naqvi; Darin Ostrander; Jeremy Sugarman; Dorry L Segev; Mark Sulkowski; Niraj M Desai Journal: Ann Intern Med Date: 2018-03-06 Impact factor: 51.598
Authors: Ji Hye Lim; Chan Jung Kim; Ju Hwan Oh; A Young Cho; Mi Ok Chang; Young Suk Kim; Kwang Young Lee; In O Sun Journal: Korean J Transplant Date: 2020-06-30
Authors: Brian J Boyarsky; Mary Grace Bowring; Ashton A Shaffer; Dorry L Segev; Christine M Durand Journal: Curr Opin Organ Transplant Date: 2019-08 Impact factor: 2.640
Authors: Susan Cuvelier; Paul Van Caeseele; Matthew Kadatz; Kathryn Peterson; Siyao Sun; Nancy Dodd; Kim Werestiuk; Joshua Koulack; Peter Nickerson; Julie Ho Journal: Can J Kidney Health Dis Date: 2021-07-26